Related Experiment Videos
MIC2 analysis in pediatric lymphomas and leukemias
M Riopel1, P S Dickman, M P Link
1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD.
Human Pathology
|April 1, 1994
Summary
Monoclonal antibodies targeting the MIC2 gene product are useful for diagnosing small round cell tumors (SRCT) in children. This study found that MIC2 expression is also prevalent in lymphoblastic lymphomas and acute lymphocytic leukemia (ALL), expanding its diagnostic utility.
Area of Science:
- Immunohistochemistry
- Pediatric Oncology
- Molecular Diagnostics
Background:
- Monoclonal antibodies to the MIC2 gene product are established markers for primitive neuroectodermal tumors and Ewing's sarcomas.
- MIC2 expression is typically negative in neuroblastomas and most rhabdomyosarcomas, aiding in the diagnosis of small round cell tumors of childhood (SRCT).
- The role of MIC2 expression in pediatric non-Hodgkin's lymphomas, which are also in the differential diagnosis of SRCT, has been less studied.
Purpose of the Study:
- To investigate MIC2 protein expression in a cohort of pediatric non-Hodgkin's lymphomas using the 12E7 antibody.
- To evaluate the utility of MIC2 expression in differentiating between various subtypes of pediatric lymphomas and leukemias.
- To determine if MIC2 expression is a reliable marker for lymphoblastic lymphomas and related leukemias within the SRCT differential.
Main Methods:
- Immunohistochemical analysis using the 12E7 antibody to assess MIC2 protein expression.
- Study included 82 pediatric non-Hodgkin's lymphomas (40 lymphoblastic, 22 small noncleaved, 20 large cell) and 125 pediatric acute lymphocytic leukemia (ALL) cases.
- Comparison of MIC2 expression patterns across different lymphoma subtypes and ALL categories (T-cell, B-cell, B-progenitor).
Main Results:
- Strong MIC2 immunoreactivity was observed in 93% of lymphoblastic lymphomas, 5% of small noncleaved lymphomas, and 20% of large cell lymphomas.
- Among pediatric ALL cases, strong MIC2 expression was noted in all T-cell ALLs, one B-cell ALL, and 77% of B-progenitor ALLs.
- Three lymphoblastic lymphomas with strong MIC2 positivity were primary bone tumors, initially considered for Ewing's sarcoma.
Conclusions:
- MIC2 expression is not exclusive to Ewing's sarcoma and primitive neuroectodermal tumors but is also strongly and reliably present in lymphoblastic lymphomas and related leukemias.
- MIC2 analysis, when used in conjunction with a panel of antibodies, remains a valuable tool in the diagnosis of SRCT.
- Further investigation is warranted to explore the potential of MIC2 analysis in distinguishing lymphoblastic lymphomas from small noncleaved lymphomas.